Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q3 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks whether management describes that its counterparties are already losing something real and ongoing (money, output, access, standing, time, opportunity) for as long as they do not have what the company provides, and that this accumulating loss is already visible in how those parties are behaving toward the company today. Also, that this dynamic is generating business meaningful relative to company size. We need to look for evidence in the transcript. The company is Surmodics, a medical device company. They have products like drug-coated balloons, microcatheters, etc. They have partnerships with Abbott for SurVeil. They mention that Abbott has options on below-the-knee and AV fistula programs. They mention multiple parties evaluating their products (Telemark microcatheter, .014 PTA balloon, .018 balloon). They have regulatory clearances and are seeking commercial agreements. Does management describe that these counterparties are losing something real and ongoing? For example, Abbott has licensed SurVeil and is paying for it. But the description of Abbott's behavior is mostly about the partnership going well, not about Abbott losing money while waiting. They mention that Abbott has options, but that's not about a running meter. For other products like Telemark microcatheter, they say "multiple parties who are conducting their own clinical evaluation." That suggests interest, but not necessarily a running meter. The only potentially relevant part is about the whole products pipeline. They say "we continue to exercise the appropriate patients in order to maximize the commercial potential for each of these devices and signed an appropriate deal for our shareholders." That's about their own patience. They also talk about the thrombectomy market, but that's about new product development. The transcript doesn't seem to describe counterparties experiencing accumulating losses. The revenue from Abbott is based on license fee and development milestones, not on Abbott losing money. The question requires both halves: (1) a running meter on the other side, and (2) the other side is already acting like the meter is running. I don't see evidence of that. Management talks about customer evaluations, but not about customers losing money while they wait.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...